Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells

Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem
Cells

Cryo-Cell Presents Study at International Society of Cellular Therapy (ISCT)
Demonstrating Potential to Expand Cord Blood Stem Cells for Possible
Utilization in Transplantation

OLDSMAR, Fla., May 5 /PRNewswire-FirstCall/ -- Cryo-Cell International, Inc.
announced results of a new study showing that adding menstrual blood stem
cells (MenSCs) to stem cells from umbilical cord blood expands the number of
progenitor cells (cells that grow into mature blood cells). This expansion
technique could broaden the therapeutic use of the cells and provide a more
readily available supply of stem cells for transplantation. These data will be
presented today at the International Society of Cellular Therapy's Annual
Meeting in San Diego, Calif.

Stem cells found in cord blood have been proven to treat more than 70
life-threatening illnesses, including leukemia, neuroblastoma, lymphoma and
sickle cell anemia. Since the first successful cord blood stem cell transplant
in 1988, cord blood stem cells have been used in more than 10,000 transplants
worldwide. Cord blood stem cells are readily available, and are easy to
collect and cryopreserve. Umbilical cord blood, however, can only be collected
at birth and does not yield a sufficient number of stem cells typically
required for transplantation - a single cord blood collection yields only
enough stem cells for a child or smaller adult. Given these limitations,
research has increasingly focused on identifying ways to expand or enhance
cord blood stem cells.

Research Summary
The studies were performed by using harvested cells from menstrual blood and
cord blood cells collected after childbirth and processed to reduce the number
of red blood cells. MenSC samples were obtained using a menstrual cup and were
transferred to a laboratory for processing and cryopreservation. Culture
results demonstrated a significant increase in the functional capacity of the
cord blood stem cells with the addition of MenSCs.

"Identifying strategies to expand the yield of cord-blood derived stem cells
has been an ongoing challenge," said Julie Allickson, Ph.D., study
investigator and Vice President, Laboratory Operations, Research and
Development at Cryo-Cell International, Inc. "Further study will confirm
whether MenSCs may be a potential solution to more readily available stem cell
sources."

"We are clearly encouraged by this research showing the potential for MenSCs
to boost the yield of cord blood stem cells - a major advance with important
possible implications to the life-saving benefits of cord blood stem cells
which may be significantly increased by utilization of this novel cell
expansion technology," said Mercedes Walton, Cryo-Cell's Chairman and CEO. "We
continue to make significant progress in advancing Cryo-Cell's robust
intellectual property portfolio which includes these newly released findings
and other groundbreaking research related to the therapeutic potential of
menstrual stem cells."

Menstrual Stem Cells in PLoS Medicine
MenSCs offer a non-controversial and renewable stem cell source that can be
collected non-invasively from what is conventionally regarded as biological
waste. Cryo-Cell discovered and identified the benefits of stem cells
harvested from menstrual blood described in a study published in the April
2008Cell Transplantation demonstrating that MenSCs have the capability to
differentiate into important cells, such as such as bone, cartilage, fat,
nerve and cardiogenic cells. Based upon these early findings, researchers
believe that MenSCs may potentially be utilized with cell-based therapies in
the future to treat serious conditions such as diabetes, heart disease,
stroke; and possibly other neurological disorders such as Alzheimer's and
Parkinson's disease. MenSCs may also potentially be utilized with customized
anti-aging, wound-healing or sports medicine therapies.

On November 1, 2007, Cryo-Cell introduced the proprietary new service
Celle(SM) based on the Company's expansive IP technology portfolio. This is
the first and only service that empowers women to collect and cryopreserve
menstrual flow containing undifferentiated adult stem cells for future
utilization by the donor or possibly first-degree relatives in a manner
similar to umbilical cord blood stem cells. Based on the continued success of
MenSCs in the research setting, Cryo-Cell is actively expanding its portfolio
of research collaborations with world renowned scientists committed to study
this novel stem cell population for a broad range of regenerative therapeutic
development. Further information about MenSCs and the ground-breaking service
is available on the website at www.Celle.com.

About Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL)
Based in Oldsmar, Florida, with over 175,000 clients worldwide, Cryo-Cell is
one of the largest and most established family cord blood banks. ISO 9001:2000
certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art
Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant
facility. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol:
CCEL. For more information, please call 1-800-STOR-CELL (1-800-786-7235) or
visit www.cryo-cell.com.

Forward-Looking Statement
Statements wherein the terms "believes", "intends", "projects" or "expects" as
used are intended to reflect "forward-looking statements" of the Company. The
information contained herein is subject to various risks, uncertainties and
other factors that could cause actual results to differ materially from the
results anticipated in such forward-looking statements or paragraphs, many of
which are outside the control of the Company. These uncertainties and other
factors include the uncertainty of market acceptance of any potential service
offerings relating to types of stem cells other than cord blood stem cells,
including the Celle service, given that menstrual stem cells and other new
stem cells have not yet been used in human therapies, and treatment
applications using such stem cells are not likely to be developed and
commercialized for many years and are subject to further research and
development; the need for additional development and testing before
determining the ultimate commercial value of the Company's intellectual
property relating to the menstrual stem cells; the need to complete certain
developments, including completion of clinical validation and testing, before
any new process other than Celle can be commercialized, and the Company's
development of its final business and economic model in offering any such
service; any adverse effect or limitations caused by recent increases in
government regulation of stem cell storage facilities; any increased
competition in our business; any decrease or slowdown in the number of people
seeking to store umbilical cord blood stem cells or decrease in the number of
people paying annual storage fees; any adverse impacts on our revenue or
operating margins due to the costs associated with increased growth in our
business, including the possibility of unanticipated costs relating to the
operation of our new facility; any technological breakthrough or medical
breakthrough that would render the Company's business of stem cell
preservation obsolete; any material failure or malfunction in our storage
facilities; any natural disaster such as a tornado, other disaster (fire) or
act of terrorism that adversely affects stored specimens; the costs associated
with defending or prosecuting litigation matters and any material adverse
result from such matters; decreases in asset valuations; any continued
negative effect from adverse publicity in the past year regarding the
Company's business operations; any negative consequences resulting from
deriving, shipping and storing specimens at a second location; and other risks
and uncertainties. The foregoing list is not exhaustive, and the Company
disclaims any obligations to subsequently revise any forward-looking
statements to reflect events or circumstances after the date of such
statements. Readers should carefully review the risk factors described in
other documents the Company files from time to time with the Securities and
Exchange Commission, including the most recent Annual Report on Form 10-KSB,
Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K filed by
the Company.

Contact:
General Media Inquiries
Tara Weintraub
312-240-2861
Tara.weintraub@edelman.com

Financial Media Inquiries
Gayatri Narayanan
212-704-4577
Gayatri.narayanan@edelman.com

SOURCE Cryo-Cell International, Inc.

General Media, Tara Weintraub, +1-312-240-2861, Tara.weintraub@edelman.com, or
Financial Media, Gayatri Narayanan, +1-212-704-4577,
Gayatri.narayanan@edelman.com, both for Cryo-Cell International, Inc.